Evolent Health, Inc.(EVH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,311 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
EVH Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Evolent Health, Inc. (EVH), a Technology sector company. 13F Pro's AI-powered ranking engine scores EVH at 31.5/100 on a 32-signal composite quality model, placing it at rank #2,311 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (21.0) and profitability (21.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 40.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Evolent Health, Inc. reports quarterly revenue of $496.2M, net income of $-26.6M, free cash flow of $-984.0K. Top institutional holders of EVH by reported 13-F value include LINDEN ADVISORS, Context Capital Management,, BlackRock,, based on the most recent SEC filings. EVH trades on the NYSE exchange and files with the SEC under CIK 1628908. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evolent Health, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$496.2M
Net Income
Q1 2026
$-26.6M
Free Cash Flow
Q1 2026
$-984.0K
D/E Ratio
Q1 2026
2.46
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-4.5% YoYNet Income
-275.6% YoYOperating Income
-475.9% YoYEPS (Diluted)
-296.1% YoYTotal Assets
-29.1% YoYTotal Debt
+62.6% YoYOp. Cash Flow
-72.8% YoY| Metric | FY 2025 | FY 2023 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $1.88B -4.5% | $1.96B +116.3% | $908.0M -1.8% | $924.6M +34.6% | $687.1M +9.6% | $627.1M |
| Net Income | $-534.5M -275.6% | $-142.3M -278.4% | $-37.6M +88.8% | $-334.2M -10.7% | $-302.0M -473.5% | $-52.7M |
| Operating Income | $-410.1M -475.9% | $-71.2M -67.9% | $-42.4M +83.9% | $-262.8M +14.9% | $-308.9M -550.6% | $-47.5M |
| EPS (Diluted) | $-5.07 -296.1% | $-1.28 -190.9% | $-0.44 +88.8% | $-3.94 -7.4% | $-3.67 | — |
| Total Assets | $1.90B -29.1% | $2.68B +88.8% | $1.42B +3.5% | $1.37B -8.4% | $1.50B -13.0% | $1.72B |
| Total Debt | $970.5M +62.6% | $597.0M +176.8% | $215.7M -25.6% | $289.9M -1.3% | $293.7M +32.9% | $221.0M |
| Operating Cash Flow | $38.8M -72.8% | $142.6M +268.0% | $38.7M +338.8% | $-16.2M +62.0% | $-42.6M -106.5% | $-20.7M |
Get alerted when EVH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Evolent Health, Inc. including:
Top Institutional Holders of EVH
LINDEN ADVISORS LP
$59.5M108,850,000 shContext Capital Management, LLC
$38.2M71,771,000 shBlackRock, Inc.
$24.8M10,888,872 shCADIAN CAPITAL MANAGEMENT, LP
$24.7M10,814,473 shPenderFund Capital Management Ltd.
$22.8M42,017,000 shMORGAN STANLEY
$20.7M9,081,079 shUBS Group AG
$18.6M8,150,361 shArena Capital Advisors, LLC- CA
$15.0M29,620,000 shDeepCurrents Investment Group LLC
$13.3M24,168,000 shRubicon Founders LLC
$13.3M5,816,123 sh
| Fund | Value | Shares |
|---|---|---|
| LINDEN ADVISORS LP | $59.5M | 108,850,000 |
| Context Capital Management, LLC | $38.2M | 71,771,000 |
| BlackRock, Inc. | $24.8M | 10,888,872 |
| CADIAN CAPITAL MANAGEMENT, LP | $24.7M | 10,814,473 |
| PenderFund Capital Management Ltd. | $22.8M | 42,017,000 |
| MORGAN STANLEY | $20.7M | 9,081,079 |
| UBS Group AG | $18.6M | 8,150,361 |
| Arena Capital Advisors, LLC- CA | $15.0M | 29,620,000 |
| DeepCurrents Investment Group LLC | $13.3M | 24,168,000 |
| Rubicon Founders LLC | $13.3M | 5,816,123 |
More Technology Companies
View all Technology →Put EVH on your watchlist
Track score changes the day Evolent Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EVH a good stock to buy?
13F Pro's AI-powered analysis of Evolent Health, Inc. (EVH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EVH are available on the EVH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own EVH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EVH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evolent Health, Inc.'s investment landscape.